# Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients

> **NCT00190242** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 99 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** group1
- **DRUG:** group2

## Key facts

- **NCT ID:** NCT00190242
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-10
- **Final completion:** 2009-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2011-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190242, "Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00190242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*